Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.33 USD
-0.03 (-2.21%)
Updated Jul 19, 2024 03:59 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATOS 1.33 -0.03(-2.21%)
Will ATOS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Other News for ATOS
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Atossa Therapeutics completes enrollment of 80mg PK run-in cohort
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
Atossa Therapeutics’ Promising Z-endoxifen Trial Data Backs Analyst’s Buy Recommendation
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer